UNITED STATES SECURITIES AND EXCHANGE COMMISSION

	Washington, D.C. 20549	
	FORM 8-K	
	CURRENT REPORT	
Pursuant to Se	ction 13 or 15(d) of the Securities Exchange	Act of 1934
Date	of Report (Date of earliest event Reported): May 7, 2020	
	MICROVISION, INC. (Exact Name of Registrant as Specified in Charter)	
Delaware (State or Other Jurisdiction of Incorporation)	001-34170 (Commission File Number)	91-1600822 (I.R.S. Employer Identification Number)
	6244 185th Avenue NE, Suite 100 Redmond, Washington 98052 (Address of Principal Executive Offices) (Zip Code)	
	(425) 936-6847 (Registrant's telephone number, including area code)	
Check the appropriate box below if the Form 8-K filing is into	ended to simultaneously satisfy the filing obligation of the	registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:		
Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value per share	MVIS	The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emer		Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the
If an emerging growth company, indicate by check mark if the		eriod for complying with any new or revised financial

If accounting standards provided pursuant to Section 13(a) of the Exchange Act. []

Item 2.02. Results of Operations and Financial Condition.

The information in this Current Report is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

On May 7, 2020, MicroVision, Inc. issued a press release announcing its First Quarter 2020 results. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits.

99.1 MicroVision, Inc. Press Release Announces First Quarter 2020 Results.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MICROVISION, INC.

Date: May 7, 2020

By: <u>/s/ David J. Westgor</u>
David J. Westgor
Vice President, General Counsel & Secretary

MicroVision Announces First Quarter 2020 Results

REDMOND, Wash., May 07, 2020 (GLOBE NEWSWIRE) -- MicroVision, Inc. (NASDAQ:MVIS), a leader in innovative ultra-miniature projection display and sensing technology, today announced its first quarter 2020 results.

Revenue for the first quarter of 2020 was \$1.5 million, compared to \$1.9 million for the first quarter of 2019. MicroVision's net loss for the first quarter of 2020 was \$4.9 million, or \$0.04 per share, compared to a net loss of \$8.1 million, or \$0.08 per share for the first quarter of 2019.

"We are committed to finding strategic alternatives that maximize the value of the Company for our stakeholders. With the help of our financial advisor, Craig-Hallum Capital Group LLC, we have approached a global list of targeted companies and are diligently exploring all options including the sale of one or more of our module product verticals and related technology or a potential sale of the Company," said Sumit Sharma, MicroVision's Chief Executive Officer.

"During the first quarter we took many steps to manage costs and create a runway that we expect will give us time to complete a strategic transaction. We transferred responsibility for component production to our April 2017 customer and sold production assets, which lowered our costs and working capital requirements. In addition, we initiated a 60% reduction to our workforce and curtailed non-essential expenses," said Sharma.

Financial Results Conference Call

The Company will host a conference call to discuss its first quarter 2020 results at 2:00 p.m. Pacific Time on Thursday, May 7, 2020. Interested parties can access the call from MicroVision's website on the Investor Relations Events Calendar page at https://microvision.gcs-web.com/investor-event-calendar or dialing 877-876-9174 (for U.S. participants) or 785-424-1670 (for participants outside of the U.S.) ten minutes prior and request to be connected to the MicroVision First Quarter Financial and Operating Results Conference Call.

The conference call will be available for rebroadcast from the Investor Relations section of MicroVision's website on the <u>Investor Relations</u> <u>Events Calendar page</u>.

About MicroVision

MicroVision is the creator of PicoP® scanning technology, an ultra-miniature sensing and projection solution based on the laser beam scanning methodology pioneered by the Company. MicroVision's platform approach for this sensing and display solution means that its technology can be adapted to a wide array of applications and form factors. We combine our hardware, software, and algorithms to unlock value for our customers by providing them a differentiated advanced solution for a rapidly evolving, always-on world.

MicroVision has a substantial portfolio of patents relating to laser beam scanning projection and sensing. MicroVision's industry leading technology is a result of its extensive research and development. The Company is based in Redmond, Washington.

MicroVision and PicoP are trademarks of MicroVision, Inc. in the United States and other countries. All other trademarks are the properties of their respective owners.

Forward-Looking Statements

Certain statements contained in this release, including those relating to strategic alternatives, sale of our product verticals or technology, sale or merger of the Company, managing costs, completing a transaction, the Company's future products and product applications and those including words like "expect" and "exploring" are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those projected in our forward-looking statements include the risk that the Company may not succeed in finding licensing or other strategic solutions, including a potential sale of the Company, with acceptable timing, benefits or costs, the Company may be unable to evidence compliance with Nasdaq criteria within the period of time that was granted by the Nasdaq panel, our ability to operate with limited cash or to raise additional capital when needed; market acceptance of our technologies and products; and for products incorporating our technologies; the failure of our commercial partners to perform as expected under our agreements, including from the impact of the COVID-19 (coronavirus); our ability to identify parties interested in paying any amounts or amounts we deem desirable for the purchase or license of intellectual property assets; our or our customers' failure to perform under open purchase orders, our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards and develop partnership opportunities; the timing of commercial product launches and delays in product development; the ability to achieve key technical milestones in key products; dependence on third parties to develop, manufacture, sell and market our products; potential product liability claims; our ability to maintain our listing on the Nasdaq Stock Market, and other risk factors identified from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K filed with the SEC. These factors are not intended to represent a complete list of the general or specific factors that may affect us. It should be recognized that other factors, including general economic factors and business strategies, may be significant, now or in the future, and the factors set forth in this release may affect us to a greater extent than indicated. Except as expressly required by federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changes in circumstances or any other reason.

MicroVision, Inc.

Balance Sheet (In thousands)

(Unaudited)

(Unaudited)			
	March 31,	December 31,	
	<u>2020</u>	<u>2019</u>	
Assets			
Current Assets			
Cash and cash equivalents	\$ 2,325	5 \$ 5,837	
Accounts receivable, net	552	•	
Inventory		- 192	
Other current assets	413		
Total current assets	3,290		
1 0 MA 0 MA 1 0 A 0 0 A 0 0 A 0 A 0 A 0 A 0 A 0 A	3,27	7,037	
Property and equipment, net	1,733	1,849	
Operating lease right-of-use asset	1,22	1,308	
Restricted cash	435	5 435	
Intangible assets, net	20^	7 221	
Other assets	18	186	
Total assets	\$ 6,904	\$ 11,836	
Liabilities and Shareholders' Equity (Deficit)			
Current Liabilities			
Accounts payable	\$ 2,113	3 \$ 1,871	
Accrued liabilities	83	· · · · · · · · · · · · · · · · · · ·	
Deferred revenue	1:		
Contract liabilities	9,27		
Other current liabilities	42		
Current portion of operating lease liability	661		
Current portion of finance lease obligations	23		
Total current liabilities	12,962		
Operating lease liability, net of current portion	1,21	1,348	
Finance lease obligations, net of current portion		5 9	
Total liabilities	14,178	3 15,813	
Commitments and contingencies			
Shareholders' Equity (Deficit)			
Common stock at par value	13:	126	
Additional paid-in capital	570,128	568,496	
Accumulated deficit	(577,533	3) (572,599)	
Total shareholders' equity (deficit)	(7,274	4) (3,977)	
Total liabilities and shareholders' equity (deficit)	\$ 6,904		
* • • · · · · · · · · · · · · · · · · ·		= =====================================	

MicroVision, Inc.
Statement of Operations
(In thousands, except earnings per share data)
(Unaudited)

Product revenue	\$ 1,247	\$ 199
License and royalty revenue	212	-
Contract revenue	10	1,652
Total revenue	 1,469	 1,851
Cost of product revenue	1,395	288
Cost of contract revenue	4	955
Total cost of revenue	 1,399	1,243
Gross margin	 70	 608
Research and development expense	3,683	5,973
Sales, marketing, general and administrative expense	1,771	2,699
Gain on disposal of fixed assets	 (450)	_
Total operating expenses	 5,004	 8,672
Loss from operations	(4,934)	(8,064)
Other expense, net	 	 (4)
Net income (loss)	\$ (4,934)	\$ (8,068)
Net income (loss) per share - basic and diluted	\$ (0.04)	\$ (0.08)
Weighted-average shares outstanding - basic and diluted	 127,214	 101,971

Investor Relations Contact

David H. Allen Darrow Associates, Inc. 408.427.4463 dallen@darrowir.com